Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Oncology | History Defined

Six Cancer Drug Approvals in One Quarter: What the FDA Cleared in Q2 2026 and Who It Helps

FDA approved 6 cancer drugs in Q2 2026, covering breast, prostate, kidney, bladder, and blood cancers. Here's what was approved, who qualifies, and what it means.

Medical Daily

A Breast Cancer Drug Decision Due July 17 Could Open a New Treatment Path for 37,000 Women a Year Who Have No Good Options Now

FDA decides on gedatolisib July 17, 2026, for HR+/HER2-/PIK3CA wild-type advanced breast cancer. A Phase 3 trial showed 76% risk reduction in progression. 37,000 patients per year.

Medical Daily

Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread

In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere – from NPR and The Washington Post to Substack and heated exchanges on social media – all circling the same…

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

GLP-1 Drugs Are Now Being Tested Alongside Chemotherapy in Cancer Patients

A University of Arizona trial is testing GLP-1 drugs with chemotherapy in metastatic pancreatic, colorectal, and liver cancer patients. Here's what the study asks.

Medical Daily

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these. David N. Cade, MD, Telix Group Chief Medical Officer...

AAP

Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific

DA NANG, Vietnam, June 18, 2026 /PRNewswire/ -- Gene Solutions announced the successful conclusion of K-CONNECT Summit 2026, a regional scientific forum that brought together leading oncology experts, clinicians, researchers and healthcare stakeholders to discuss how Artificial Intelligence (AI) and multi-omics are reshaping cancer care across Asia-Pacific.Held in Da Nang,…

AAP

Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 million

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Personalized mRNA Cancer Vaccine Shows Five-Year Data Stunning Oncologists with 69 Percent of Stage III IV Melanoma Patients Cancer-Free

ASCO 2026 (June 3, 2026) and Journal of Clinical Oncology: Intismeran autogene + Keytruda shows 49% sustained recurrence reduction at 5 years, 59% distant metastasis reduction, and 53% overall survival benefit in high-risk Stage III/IV melanoma. 69% of combination patients are cancer-free at 5 years.

Medical Daily

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

FLORENCE, Italy and NEW YORK, June 14, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal…

AAP

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat

Infosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform global

Precision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform, OncoTwin. The company aims to make precision oncology inclusive for under-represented populations. 4baseCare is also decentralising genomic testing infrastructure in India. This move brings advanced cancer diagnostics closer…

The Economic Times

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York. Kuan said the company believes the therapy cou

MarketBeat

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

MarketBeat

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

Medical Daily

National Cancer Survivors Day Is Sunday — And for Dallas's Pancreatic Cancer Patients, There Has Never Been More Reason to Celebrate

National Cancer Survivors Day arrives with unprecedented hope for Dallas-Fort Worth pancreatic cancer patients as a breakthrough new drug nearly doubles survival in a landmark Phase 3 trial, marking a major advance against one of the deadliest cancers.

France 24

Cancer breakthroughs: Does a string of advances signal turning point?

It’s not every day that a standing ovation at a medical conference goes viral. Dateline: Chicago, at the annual conference of the American Society of Clinical Oncology. Doctors from around the world rose to their feet to applaud the announcement of a new pill that doubles survival time for pancreatic…

MarketBeat

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference

Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company’s focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

"Transformative Advance" in Cancer Treatment Emerges in Dallas — New Pill Shows Rare Survival Jump in Pancreatic Cancer Patients

Pancreatic Cancer treatment may be entering a new era as a breakthrough pill nearly doubles survival in metastatic patients, offering new hope for one of the deadliest forms of cancer.

The Times of India

How a $150 million gift brought Texas Children’s and MD Anderson together for childhood cancer

A significant donation of $150 million from the Kinder Foundation is uniting Texas Children's Hospital and UT MD Anderson Cancer Center. This gift supports the new Kinder Children's Cancer Center. The initiative focuses on merging existing strengths in pediatric care and cancer research. The goal is to bridge the gap…

Medical Daily

New Cancer Treatments Show Promise Against Some of the Deadliest Tumors, Researchers Report

The developments were highlighted during presentations at major oncology meetings and reported by The Guardian on June 1, as researchers unveiled data suggesting that several next-generation treatments may improve outcomes for patients who have exhausted standard options.

MarketBeat

ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs

ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004. S

The Economic Times

Avammune’s big bet: Why the future of cancer treatment may come in a pill

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherapies designed for broader patient access.

The Guardian - UK

Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest

Three studies add to evidence that jabs could be part of cancer-fighting toolkit to cut risk of developing or dying from disease

MarketBeat

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human p

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.